Letters to the EditorMASSIVE FACTOR-VIII INFUSION IN HÆMOPHILIAC WITH FACTOR-VIII INHIBITOR, HIGH RESPONDER
References (5)
- et al.
Blood
(1976) - et al.
Thromb. Diath. hœmorth
(971)
Cited by (227)
Immune tolerance induction in development
2023, BloodAdeno-associated virus-vectored delivery of HIV biologics: the promise of a “single-shot” functional cure for HIV infection
2023, Journal of Virus EradicationHemophilia treatment innovation: 50 years of progress and more to come
2023, Journal of Thrombosis and HaemostasisImmune complications and their management in inherited and acquired bleeding disorders
2022, BloodCitation Excerpt :Three approaches to this problem have been developed (Figure 1): induction of antigen-specific immune tolerance (ITI), immune suppression therapy (IST), and restoring hemostasis through alternative molecules or pathways to circumvent the antibody blockade (such as bypass therapies, bispecific antibodies that mimic the function of FVIII or suppression of anticoagulant pathways). Antigen-specific ITI protocols were first used in the 1970s and showed that frequent IV delivery of FVIII can eliminate inhibitors.2 Furthermore, ITI protocols not only eradicate ADA but also promote lasting tolerance, serving as an important proof of principle that antigen-specific tolerance to the therapeutic drugs can be achieved in replacement therapy for genetic diseases.
Secondary failure: immune responses to approved protein therapeutics
2021, Trends in Molecular MedicineThe 3.2 Å structure of a bioengineered variant of blood coagulation factor VIII indicates two conformations of the C2 domain
2020, Journal of Thrombosis and Haemostasis